Literature DB >> 12131554

Isoproterenol and angiotensin I-converting enzyme in lung, left ventricle, and plasma during myocardial hypertrophy and fibrosis.

María Paz Ocaranza1, Guillermo Díaz-Araya, Mario Chiong, David Muñoz, Juan Pablo Riveros, Roberto Ebensperger, Sebastián Sabat, Pablo Irarrázaval, Jorge E Jalil, Sergio Lavandero.   

Abstract

This study investigated whether long-term administration of isoproterenol (ISO) induces differential expression of angiotensin-converting enzyme (ACE) in lung, plasma, and left ventricle (LV) during development of left ventricular hypertrophy (LVH) and myocardial fibrosis. Male Sprague-Dawley rats (n = 7-9 per group) were treated with isoproterenol (ISO) 5 mg/kg per day for 10 days or saline and examined at 1, 15, and 33 days after the last injection. ISO stimulated the development of left ventricular hypertrophy (LVH); relative LV weight (mg LV 100/body weight), LV protein content, and LV beta-myosin heavy chain levels increased at day 1. LVH regressed at days 15 and 33. ISO also increased myocardial fibrosis (assessed by hydroxyproline content and morphometry) at days 15 and 33. There no were changes in arterial blood pressure. Long-term beta-adrenergic stimulation with ISO increased ACE expression in lung, LV, and plasma during development of LVH and myocardial fibrosis. However, time courses were markedly different. ISO stimulated a sustained increase in lung and plasma ACE activities, whereas ISO induced a high LV ACE. Plasma ACE activity paralleled lung ACE activity. LV ACE activity correlated with ACE mRNA levels and paralleled development of LVH. Our data suggest long-term beta-adrenergic stimulation induced a differential temporal expression of LV, lung, and plasma ACE in rat during development of LVH and myocardial fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12131554     DOI: 10.1097/00005344-200208000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects.

Authors:  Oleg E Osadchii
Journal:  Heart Fail Rev       Date:  2007-03-27       Impact factor: 4.654

2.  Mouse models for the study of postnatal cardiac hypertrophy.

Authors:  A Del Olmo-Turrubiarte; A Calzada-Torres; G Díaz-Rosas; I Palma-Lara; R Sánchez-Urbina; N A Balderrábano-Saucedo; H González-Márquez; P Garcia-Alonso; A Contreras-Ramos
Journal:  Int J Cardiol Heart Vasc       Date:  2015-03-06

3.  Geniposide Alleviates Isoproterenol-Induced Cardiac Fibrosis Partially via SIRT1 Activation in vivo and in vitro.

Authors:  Ning Li; Heng Zhou; Zhen-Guo Ma; Jin-Xiu Zhu; Chen Liu; Peng Song; Chun-Yan Kong; Hai-Ming Wu; Wei Deng; Qi-Zhu Tang
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

4.  Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'.

Authors:  Stefanie Maria Werhahn; Julia S Kreusser; Marco Hagenmüller; Jan Beckendorf; Nathalie Diemert; Sophia Hoffmann; Jobst-Hendrik Schultz; Johannes Backs; Matthias Dewenter
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

5.  Angiotensin (1-7) and Apelin co-therapy: New strategy for heart failure treatment of rats.

Authors:  Ava Soltani Hekmat; Kazem Javanmardi; Alireza Tavassoli; Yousof Gholampour
Journal:  Anatol J Cardiol       Date:  2020-03       Impact factor: 1.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.